StockData
Atrium Therapeutics, Inc. logo

Atrium Therapeutics, Inc. (RNA) shareholders

RNANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$6.48+0.05 (+0.78%)

Close on Nov 17, 2026Market cap $110.85MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
90.6%
15M of 17M shares
Institutional holders
155
40 new, 46 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
John Petry
Joint filing with Sessa Capital IM, L.P. (8.80%)
1,500,0008.80%13G (passive)Jun 30, 2026
T. Rowe Price Associates, Inc.1,472,9848.60%13G (passive) amendmentJun 30, 2026
BlackRock, Inc.1,135,7576.60%13G (passive) amendmentJun 30, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of RNAValueChange% of portfolio
Sessa Capital IM, L.P.1,500,0008.77%$20.18M+948,6090.34%
Price T Rowe Associates Inc /Md/1,472,9848.61%$19.81M−80,2260.00%
BlackRock, Inc.1,447,4768.46%$19.47M+242,1850.00%
Crcm LP1,283,0787.50%$17.26MNew5.68%
Vanguard Capital Management LLC730,8314.27%$9.83M+103,9620.00%
TIG Advisors, LLC561,5333.28%$7.55M−46,0190.33%
Arbiter Partners Capital Management LLC522,5763.05%$7.03M+292,5761.85%
Cantor Fitzgerald, L. P.513,8343.00%$6.91M+278,1970.04%
Geode Capital Management, LLC386,9292.26%$5.21M+67,0980.00%
Two Sigma Investments, LP345,4812.02%$4.65M+166,9210.00%
Goldman Sachs Group Inc310,3411.81%$4.17M−39,6090.00%
683 Capital Management, LLC300,0001.75%$4.04M–0.20%
State Street Corp271,7621.59%$3.66M+14,6760.00%
Slotnik Capital, LLC237,6371.39%$3.20M+56,6920.83%
Weiss Asset Management LP219,7301.28%$2.96M−20,9710.03%
Millennium Management LLC200,5591.17%$2.70M+9,7000.00%
Schonfeld Strategic Advisors LLC199,1581.16%$2.68M+36,3990.01%
Aqr Capital Management LLC172,2351.01%$2.32MNew0.00%
Nexpoint Asset Management, L.P.150,0250.88%$2.02M–0.13%
Polar Asset Management Partners Inc.150,0000.88%$2.02M+80,0000.03%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202615515M90.6%40 / 4735 / 465M4M
Q1 202616315M86.7%163 / 00 / 015M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

156 funds held RNA in Q2 2026, 43% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of RNAValue% of fundAs of
T. Rowe Price Health Sciences Fund, Inc.566,4283.31%$7.62M0.06%Jun 30, 2026
Vanguard Total Stock Market Index Fund518,4163.03%$6.97M0.00%Jun 30, 2026
T. Rowe Price New Horizons Fund, Inc.443,2632.59%$5.96M0.04%Jun 30, 2026
iShares Russell 2000 ETF377,3542.21%$5.08M0.01%Jun 30, 2026
Vanguard Extended Market Index Fund188,6261.10%$2.54M0.00%Jun 30, 2026
BlackRock Event Driven Equity Fund175,3881.03%$2.28M0.05%May 29, 2026
Fidelity Small Cap Index Fund154,1790.90%$1.75M0.01%Jul 31, 2026
Nexpoint Merger Arbitrage Fund135,1380.79%$1.82M0.12%Jun 30, 2026
iShares Russell 2000 Growth ETF88,1070.52%$1.19M0.01%Jun 30, 2026
Fidelity Extended Market Index Fund73,5330.43%$955.93K0.00%May 31, 2026
Schwab U.S. Small-Cap ETF67,6390.40%$879.31K0.00%May 31, 2026
Vanguard Russell 2000 Index Fund62,8890.37%$817.56K0.00%May 31, 2026
iShares Micro-Cap ETF48,1840.28%$648.07K0.04%Jun 30, 2026
T. Rowe Price Health Sciences Portfolio41,7000.24%$560.87K0.07%Jun 30, 2026
iShares Russell 2000 Value ETF41,0900.24%$552.66K0.00%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Kathleen P. GallagherSee Remarks, Director119,7290.70%Sep 22, 2026
Husam YounisChief Scientific Officer41,4410.24%Sep 22, 2026
Steven George HughesChief Medical Officer51,6380.30%Sep 22, 2026
Brendan R. WinslowChief Financial Officer36,8590.22%Sep 22, 2026
Stephanie KenneySee Remarks33,0850.19%Sep 22, 2026
Rocio Martin HoyosChief Strategy Officer38,3400.22%Sep 22, 2026
W. Michael FlanaganDirector31,9740.19%Sep 22, 2026
Sarah BoyceDirector138,6680.81%Sep 22, 2026
Carsten BoessDirector11,0050.06%Mar 2, 2026
Simona SkerjanecDirector5,9020.03%Mar 2, 2026
Troy Edward WilsonDirector11,7310.07%Mar 2, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Steven George Hughes
Chief Medical Officer
Sep 18, 2026Tax withholding−21,459$8.95$192.06K51,638
Stephanie Kenney
See Remarks
Sep 18, 2026Tax withholding−2,375$8.95$21.26K33,085
Brendan R. Winslow
Chief Financial Officer
Sep 18, 2026Tax withholding−6,742$8.95$60.34K36,859
Rocio Martin Hoyos
Chief Strategy Officer
Sep 18, 2026Tax withholding−8,320$8.95$74.46K38,340
Sarah Boyce
Director
Sep 18, 2026Tax withholding−126,418$8.95$1.13M138,668
Kathleen P. Gallagher
See Remarks, Director
Sep 18, 2026Tax withholding−11,632$8.95$104.11K119,729
Husam Younis
Chief Scientific Officer
Sep 18, 2026Tax withholding−11,216$8.95$100.38K41,441
W. Michael Flanagan
Director
Sep 18, 2026Tax withholding−22,812$8.95$204.17K31,974
Husam Younis
Chief Scientific Officer
Apr 20, 2026Award+30,000––52,657
Steven George Hughes
Chief Medical Officer
Apr 20, 2026Award+30,000––73,097
Rocio Martin Hoyos
Chief Strategy Officer
Apr 20, 2026Award+30,000––46,660
Kathleen P. Gallagher
See Remarks, Director
Apr 20, 2026Award+102,500––131,361
Brendan R. Winslow
Chief Financial Officer
Apr 20, 2026Award+30,000––43,601
Stephanie Kenney
See Remarks
Apr 20, 2026Award+30,000––35,460

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
22.61%
4M shares short
Days to cover
16.1
At 0M shares a day
Change since last report
+0.6%
From 4M shares
Short volume, 20 days
39.1%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Atrium Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 3,946 shares on Aug 21, 2026 over the last 90 days.

See a number that looks wrong?